
Illustration showing how miniature artificial protocells loaded with anti-microRNA-223 cargo can reprogram cancer-associated macrophages in larval and adult zebrafish leading them to be more pro-inflammatory and thus able to drive melanoma shrinkage
CREDIT: Paco Lopez Cuevas
Discovery demonstrates a new way to clear early stage pre-cancerous and even late-stage tumour cells
A new way of reprogramming our immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard to treat and devastating skin cancer, melanoma. The University of Bristol-led discovery, published in Advanced Science today [31 October], demonstrates a new way to clear early stage pre-cancerous and even late-stage tumour cells.
Using miniature artificial capsules called protocells designed to deploy reprogramming cargoes that are taken up by inflammatory cells (white blood cells), the scientists show they were able to transform these cells into a state that makes them more effective at slowing down the growth and killing of melanoma cells. They showed that this was possible for both animal and human immune cells.
The study is the first to test the capacity of a protocell to deliver cargoes for reprogramming immune cells and offers a promising novel target for the development of cancer immunotherapies.
Paul Martin, Professor of Cell Biology in the School of Biochemistry at the University of Bristol and one of the study’s lead authors explained what happens when our immune system comes into contact with cancer cells: “Our immune cells have a surveillance capacity which enables them to detect pre-cancerous cells arising at any tissue site in the body. However, when immune cells encounter cancer cells they are often subverted by the cancer cells and instead tend to nourish them and encourage cancer progression. We wanted to test whether it might be possible to reprogramme our immune system to kill these cells rather than nurture them.”
First, the team tested the proof of concept in zebrafish larvae which are used due to their translucency, allowing researchers to watch inflammatory immune cells interact with cancer cells in ways not possible in our own tissues.
Protocells loaded with anti-miR223 molecules that bind to and interfere with signalling machinery in the inflammatory immune cells and work by effectively prolonging their pro-inflammatory state, were shown to drive altered immune cell-cancer cell interactions, slowing the growth of cancerous cells and driving increased tumour cell death in the larvae.
To find out whether this approach might be upscaled as a feasible therapeutic strategy for shrinking larger, more established, and growing cancers, the experiment was repeated in adult fish with tailfin melanomas, showing this approach significantly inhibited melanoma cell growth.
To fully investigate the feasibility of using protocells to deliver ‘reprogramming’ anti-miR223 cargoes in humans, the experiment was conducted again using an in vitro assay with primary human immune cells from the Toye lab, also in Bristol’s School of Biochemistry. Results from this experiment demonstrated that the protocells were able to effectively deliver and reprogramme human immune cells toward a more persistent pro-inflammatory and potentially anti-cancer state.
Professor Stephen Mann from Bristol’s School of Chemistry and the Max Planck Bristol Centre for Minimal Biology added: “Our results highlight the therapeutic benefits of harnessing host immunity to eradicate cancers and demonstrate the feasibility of using protocells to deliver cargoes for reprogramming innate immune cells. While our experiments in zebrafish are early pre-clinical studies, our results indicate that the same is possible for human immune cells, at least in vitro, and can be similarly reprogrammed to supress cancer growth.”
Original Article: Reprogramming of immune cells shown to fight off melanoma
More from: University of Bristol
The Latest Updates from Bing News
Go deeper with Bing News on:
Reprogramming immune cells
- Improving CAR-based-immunotherapies using a molecular anchor
Peter Chockley, Ph.D., first and corresponding author, St. Jude Department of Bone Marrow Transplantation and Cellular Therapy Scientists can reprogram human immune cells to target cancer cells by ...
- St. Jude scientists create more efficient CAR immunotherapies using a molecular anchor
St. Jude scientists added a small physical structure called an anchor domain to the CAR molecule. The anchor domain connects the CAR to the internal infrastructure of the immune cell. It augments and ...
- Someday, You Might Be Able to Eat Your Way Out of a Cold
It all has a way of making real science sound like garbage. Research on nutrition and immunity “has been ruined a bit by all the writing out there on Eat this to cure cancer,” Lydia Lynch, an ...
- Umbilical stem cells may be the ‘answer to a number of diseases’
“Umbilical cord stem cells are currently used to treat many life-threatening diseases, including cancer, blood disorders, immune disorders and metabolic ... ‘for the discovery that mature cells can be ...
- How to tell if your immune system is weak or strong
Let’s begin by considering the different components. The first line of defence comes from innate immune cells such as macrophages, which engulf bacteria and release chemicals that trigger inflammation ...
Go deeper with Bing News on:
Inhibiting melanoma cell growth
- Sirnaomics seeks FDA guidance for phase III skin cancer candidate
Sirnaomics Ltd. is gearing up to start a phase III clinical trial for its lead siRNA candidate, STP-705, for the treatment of two non-melanoma skin cancers: squamous cell carcinoma in situ and basal ...
- The size of skin cancer cells may affect how they respond to treatment
Smaller melanoma skin cancer cells may be more vulnerable to drugs that block DNA repair, while larger cells might be more responsive to immunotherapy ...
- Cancer Cells Resist Treatment by Manipulating Their Size
London, combined biochemical profiling technologies with mathematical analyses and found that cancer cells can shrink or super size to survive drug treatment or other obstacles in their environment.
- Cancer Cells Change Size to Survive Chemotherapy
These larger cells were not as reliant on DNA repair machinery, so using chemotherapy and PARP inhibitors ... division, growth and maintaining the cytoskeleton - and its interactions with other ...
- Cancer Cells Shrink or Expand To Resist Treatments
The size of cancer cells could be a good indicator of how they will respond to different treatments, as new research reports that cancer cells can change in size to survive.